Published in Drug Law Weekly, March 20th, 2007
The drug discovery programme focuses on the development of small molecule inhibitors of an undisclosed kinase. The collaboration builds on a series of validated hit compounds possessing relevant cell-based activity, identified by leading Fox Chase research scientists. Hit to lead studies to optimise potency and drug-like characteristics of the compounds will be performed in CRT's development laboratories located in London, UK. Novel small...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.